➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Express Scripts
Harvard Business School
Dow

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,029,533


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,029,533 protect, and when does it expire?

Patent 9,029,533 protects ICLUSIG and is included in one NDA.

This patent has seventy-one patent family members in twenty countries.

Summary for Patent: 9,029,533
Title:Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Abstract: This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use.
Inventor(s): Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Sharon, MA), Romero; Jan Antoinette C. (Somerville, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Watertown, MA), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA)
Assignee: ARIAD Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/801,116
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,029,533

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR THE TREATMENT OF LEUKEMIAS ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Free Forever Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD FOR THE TREATMENT OF LEUKEMIAS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,029,533

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006331673 ⤷  Free Forever Trial
Australia 2007249924 ⤷  Free Forever Trial
Australia 2007249926 ⤷  Free Forever Trial
Brazil PI0621098 ⤷  Free Forever Trial
Brazil PI0710328 ⤷  Free Forever Trial
Brazil PI0710331 ⤷  Free Forever Trial
Canada 2634923 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Boehringer Ingelheim
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.